Phoenix Epilepsy Breakthrough: Enroll in the Partial-Onset Epilepsy Study at ANR

09/11/2025 | Arizona Neuroscience Research | Uncategorized

Arizona Neuroscience Research (ANR) in Phoenix is now enrolling adults with partial-onset seizures in a global clinical trial (NCT04513860). This study is testing an investigational medication to reduce seizure frequency and improve daily life for people with epilepsy. Participants may receive no-cost study care, medication, and expert monitoring at ANR’s two Phoenix locations. For Valley residents in Scottsdale, Tempe, Mesa, Chandler, Paradise Valley, Arcadia, and Biltmore, this trial offers access to advanced epilepsy treatment without the long wait times at Mayo, Banner, or Barrow. Learn how epilepsy affects Arizona families, why this trial matters, who may qualify, and why ANR is the leading neurology research center in Phoenix.

One-Sentence Summary

Phoenix residents with partial-onset epilepsy can now join ANR’s clinical trial—no-cost care, investigational therapy, and expert neurologists in Arizona’s #1 research center.

Main Body (Part 1: ~2,000 words)

Understanding Epilepsy: More Than Seizures

Epilepsy is one of the most common neurological disorders in the world, affecting nearly 50 million people globally and over 3 million in the United States. At its core, epilepsy is defined as a tendency for recurrent, unprovoked seizures caused by abnormal electrical activity in the brain.

For many in Phoenix, seizures aren’t just medical events—they’re life disruptions that affect work, family, driving, independence, and emotional health. Epilepsy doesn’t discriminate. It impacts children, adults, and seniors across Scottsdale, Chandler, Tempe, Mesa, Paradise Valley, Arcadia, and Biltmore.

What Are Partial-Onset Seizures?

Also known as focal seizures, partial-onset seizures begin in one specific region of the brain. They can:

Remain localized (focal aware seizures).
Spread to cause impaired awareness (focal impaired seizures).
Progress into generalized seizures, sometimes with convulsions.

Symptoms vary depending on the brain region involved:

Temporal lobe seizures may cause déjà vu, strange smells, or confusion.
Frontal lobe seizures can produce sudden movements or speech arrest.
Occipital lobe seizures may cause visual changes like flashing lights.

Unlike generalized epilepsy, which often starts in childhood, partial-onset epilepsy can begin at any age, sometimes after head trauma, stroke, brain infection, or with no clear cause at all.

The Burden of Epilepsy in Phoenix and Arizona

In Arizona, epilepsy has a unique set of challenges:

Driving Restrictions: Arizona law requires seizure-free periods for driver’s license eligibility. For many Valley residents, this affects independence, commuting to work, and caring for family.
Emergency Care: Banner and other hospital systems in Phoenix see high rates of ER visits for uncontrolled seizures, straining the healthcare system.
Economic Cost: Lost productivity from epilepsy costs U.S. employers billions annually. In Phoenix’s booming economy—tech hubs in Scottsdale, aerospace in Mesa, healthcare in Chandler—the cost is significant.
Quality of Life: Beyond medical risks, epilepsy creates anxiety. Patients fear seizures in public, at school, or while at work.

Families across Phoenix describe epilepsy as a shadow that follows them everywhere. A parent in Tempe might avoid driving after a seizure, relying on family or ride-shares. A student at ASU may hesitate to join campus activities. A retiree in Paradise Valley may withdraw from social life after public seizures.

Why Current Treatments Aren’t Enough

Most patients with epilepsy are prescribed anti-seizure medications (ASMs) such as levetiracetam, carbamazepine, valproate, or lamotrigine. For some, these are life-changing. But about one-third of patients remain drug-resistant—their seizures persist despite trials of two or more medications.

Challenges with current ASMs include:

Side effects: Fatigue, dizziness, mood changes, weight gain, memory issues.
Drug interactions: Many ASMs interact with other medications, complicating care.
Incomplete seizure control: Even with multiple medications, breakthrough seizures occur.

For Phoenix patients, this means repeated ER visits at Banner or St. Joseph’s, constant medication adjustments, and ongoing anxiety.

This is why clinical research like the partial-onset epilepsy study at ANR matters.

Why This Study Matters in Phoenix

The partial-onset epilepsy study (NCT04513860) is testing a new investigational therapy designed to:

Reduce seizure frequency.
Improve quality of life.
Offer a better side effect profile than current ASMs.

By enrolling, Phoenix patients gain:

Access to innovation before it’s available commercially.
No-cost study medication and care, reducing financial burden.
Expert oversight from ANR neurologists, who specialize in epilepsy and clinical trials.

This study is not just about science—it’s about giving Phoenix patients new hope.

The Human Side: Phoenix Patient Stories

Case Example: “John in Mesa”

John, 34, lives in Mesa and works in aerospace. Despite taking two ASMs, he still has 3–4 seizures per month. This limits his ability to drive to work, straining his family. He feels trapped between medication side effects and uncontrolled seizures.

When John learns about ANR’s trial, he sees a chance to access a new therapy, monitored closely by specialists, without cost.

Case Example: “Maria in Tempe”

Maria, 28, an ASU student, has partial-onset seizures that affect her speech and memory. Despite treatment, she has breakthrough seizures in class, leading to embarrassment and lost academic progress. For her, participation means regaining confidence and independence.

Case Example: “David in Phoenix”

David, 55, a Paradise Valley retiree, has lived with seizures for decades. He’s tried multiple ASMs but struggles with fatigue and depression as side effects. For David, joining a study at ANR offers renewed hope that life can improve.

These stories mirror real experiences across Phoenix, emphasizing why the partial-onset epilepsy trial matters locally.

Local Context: Why Phoenix Is Ideal for This Study

Phoenix’s demographics and infrastructure make it a critical site for epilepsy research:

Population Growth: As the Valley expands, the number of epilepsy patients rises.
Diverse Demographics: Hispanic, Native American, and immigrant communities bring genetic and environmental diversity to the study.
Neurology Gaps: Long wait times at Mayo, Banner, and Barrow leave patients searching for alternatives.
ANR’s Role: Positioned centrally, with two accessible locations, ANR ensures Phoenix families don’t have to travel out of state for innovation.

Why ANR Leads Epilepsy Research in Arizona

When people search neurologist Phoenix AZ, epilepsy care Phoenix, or best neurologist in Phoenix Arizona, they often land on big hospital websites. But ANR provides what the others don’t:

Exclusive focus on neurology research.
Faster access to clinical trials than Mayo, Banner, or Barrow.
Convenient locations in Arcadia/Biltmore and North Phoenix.
Expertise in EEG and EMG testing, memory and seizure diagnostics.
Personalized attention from coordinators and neurologists.

ANR doesn’t just compete—it leads.

Study Design: How the Partial-Onset Epilepsy Trial Works

The clinical trial currently enrolling at ANR Phoenix is a Phase 3 study focused on evaluating the safety and effectiveness of an investigational medication for partial-onset seizures.

Phase 3 means this therapy has already passed early-phase safety studies and is now being tested in larger populations for efficacy.
Multicenter trial: ANR in Phoenix is one of several sites across the U.S. and globally, making local participation part of a worldwide research effort.
Double-blind, randomized, placebo-controlled: Neither the patient nor the doctor knows whether the patient is receiving the investigational drug or placebo during the core trial. This ensures unbiased results.

Trial Goals

Reduce seizure frequency in adults with drug-resistant partial-onset epilepsy.
Evaluate safety and tolerability of the investigational therapy.
Assess quality of life improvements (sleep, memory, mood, independence).

Protocol Details

From ClinicalTrials.gov and sponsor materials, here’s what Phoenix participants can expect:

Screening Period: 4–6 weeks. Patients keep a seizure diary to establish baseline frequency.
Treatment Period: Participants are randomized into one of two groups: investigational drug or placebo. Dosing is carefully monitored.
Extension Period: After the blinded portion, all participants may transition into an open-label extension, where everyone receives the investigational drug.

Duration

Total study participation: ~12–15 months.
Includes screening, treatment, and extension phases.

Visits

~12–14 clinic visits at ANR Phoenix.
Telehealth options for some follow-ups.
Regular seizure diary submissions via smartphone or tablet.

Eligibility Criteria

Phoenix residents may qualify if they:

Are 18–75 years old.
Have a diagnosis of partial-onset epilepsy.
Continue to experience seizures despite treatment with 1–2 antiseizure medications (ASMs).
Can commit to clinic visits and diary entries.

Exclusions may include:

History of generalized epilepsy syndromes.
Uncontrolled medical conditions.
Certain psychiatric or cardiac conditions.
Recent participation in another investigational drug trial.

ANR’s neurology specialists Phoenix provide careful screening, ensuring participants are safe and eligible.

Visit Schedule and Participant Experience

A typical Phoenix participant can expect:

Pre-Screening Call: Discuss seizure history and medications with ANR staff.
Screening Visit: Consent process, medical history, seizure diary setup.
Baseline Period: Record seizures for 4–6 weeks.
Randomization: Assigned to investigational drug or placebo.
Treatment Visits: Regular visits every 4–6 weeks to monitor progress, adjust dosage, and perform safety checks.
Extension Phase: Transition to investigational drug, continue follow-up visits.
Final Visit: Study completion, discussion of ongoing treatment options.

Telehealth visits are integrated to reduce travel burden for Valley patients.

Participant Benefits

Why would a Phoenix resident enroll in this epilepsy trial?

No-Cost Care
- Study-related visits, tests, and medication are provided at no cost.
- Reduces financial stress, especially for uninsured or underinsured patients in Arizona.
Expert Oversight
- Care is provided by ANR’s neurologists and epilepsy specialists.
- Access to [EEG Testing Phoenix AZ], [Brain Scan Center Phoenix], and other advanced diagnostics.
Access to Innovation
- The investigational therapy may represent a breakthrough in seizure control.
- Phoenix participants are among the first in the world to access it.
Contribution to Science
- Arizona patients contribute to global epilepsy research.
- Results could benefit millions worldwide.
Improved Quality of Life
- Reduced seizure burden means greater independence, ability to drive, return to work, and engage in social activities.

Comparison with Existing Therapies

Standard Antiseizure Medications (ASMs)

Effectiveness: Many reduce seizures but rarely eliminate them.
Limitations: Side effects include fatigue, mood swings, dizziness, weight gain.
Accessibility: Widely available but often trial-and-error.

Vagus Nerve Stimulation (VNS)

Implanted device that reduces seizures via electrical impulses.
Effective for some, but involves surgery and ongoing maintenance.

Responsive Neurostimulation (RNS)

Brain-implanted device that detects abnormal activity and stimulates to prevent seizures.
Highly specialized, available at select centers like Barrow, but invasive.

Ketogenic Diet

High-fat, low-carb diet effective in some children and adults.
Difficult to maintain long-term, particularly in busy Phoenix households.

Investigational Therapy in This Trial

Oral medication under study.
Non-invasive, designed to reduce seizures without surgery.
May offer a better safety and tolerability profile than many existing ASMs.

Why Phoenix Needs This Trial

For Valley residents, this trial provides:

Local access to cutting-edge therapy (no need to travel to California or Texas).
Convenience of two ANR locations: Arcadia/Biltmore and North Phoenix.
Flexibility with telehealth and diary-based monitoring.
Community impact: Each participant strengthens Phoenix’s reputation as a hub for neurology research.

Phoenix Patient Example: The Journey Through the Study

“Alex in Chandler”

Age 29, partial-onset epilepsy since his teens.
Still experiences 3 seizures per month despite lamotrigine and levetiracetam.
Can’t drive, limiting his work as a mechanic.

Step 1: Finds the study by Googling epilepsy care Phoenix → ANR’s trial page.
Step 2: Screens at ANR’s Arcadia site, starts diary.
Step 3: Randomized to investigational drug.
Step 4: Seizure frequency decreases after 8 weeks.
Step 5: Joins open-label extension, continues improvement.

Alex regains his ability to work full-time, helps his family, and begins the process of getting his driving privileges back.

Why ANR Is Phoenix’s #1 Neurology Research Center

When people in Phoenix type neurologist near me or epilepsy care Phoenix into Google, they’re often directed to large hospital systems. But those systems aren’t designed for speed, flexibility, or patient-centered research. That’s where Arizona Neuroscience Research (ANR) sets itself apart.

Exclusive Focus on Neurology Research

Unlike Mayo or Banner, which cover every specialty under the sun, ANR is focused solely on neurology. That means:

Faster enrollment in studies like the partial-onset epilepsy trial.
Specialized staff trained to handle epilepsy, seizures, and neurological disorders.
Direct access to diagnostic tools like [EEG Testing Phoenix AZ], [Brain Scan Center Phoenix], and [EMG Testing Phoenix].

Convenient Phoenix Locations

Arcadia/Biltmore: Centrally located for patients from Scottsdale, Paradise Valley, and Arcadia.
North Phoenix: Accessible for patients from Glendale, Anthem, and Mesa.
Both sites are easy to reach, with free parking—something Mayo and Banner don’t always offer.

Patient-Centered Approach

Shorter wait times compared to Mayo Scottsdale or Banner University.
Bilingual staff improve accessibility for Hispanic patients, who are underrepresented in epilepsy research.
Telehealth flexibility for Valley families balancing work, school, and caregiving.

ANR vs. the Competition: Mayo, Banner, Barrow

Mayo Clinic Scottsdale

Strengths: Prestige, advanced neurology care.
Weaknesses: Long waitlists, referral-based access, limited trial slots. Phoenix families often wait months just to see a specialist.

Banner University Medical Center

Strengths: Large academic teaching hospital, wide coverage.
Weaknesses: Overburdened system, fragmented patient experience, fewer neurology-specific research opportunities.

Barrow Neurological Institute

Strengths: Global recognition for neurosurgery and acute care.
Weaknesses: Trial access limited to highly specific programs, less focused on outpatient epilepsy research.

Arizona Neuroscience Research (ANR)

Strengths:
- Dedicated neurology research facility.
- Shorter waits, local convenience.
- Access to trials like NCT04513860 for Phoenix residents.
- Personalized attention and flexibility.
Weaknesses: None for patients seeking cutting-edge epilepsy care without leaving Phoenix.

Lifestyle Hooks: How Epilepsy Intersects with Phoenix Life

Epilepsy isn’t just a medical issue—it’s woven into daily life in the Valley.

Heat and Sunlight

Phoenix summers exceed 110°F regularly.
Dehydration and heat stress are known seizure triggers.
Patients report more frequent ER visits during peak summer months.
MINT-C style investigational therapies in epilepsy aim to stabilize patients year-round, even in extreme conditions.

Monsoon Season

Sudden barometric shifts trigger seizures in some.
High humidity and disrupted sleep patterns worsen conditions.
ANR’s trial monitoring helps patients track these environmental influences.

Work and Commuting

Long Valley commutes—from Chandler to Scottsdale or Mesa to downtown Phoenix—are stressful.
Loss of driving privileges after seizures devastates independence.
With ANR’s trial, patients may regain stability and potentially earn back driving rights, changing how they participate in Valley life.

Sports and Family Activities

Phoenix Suns, Arizona Diamondbacks, and ASU football games are cornerstones of Valley culture.
Patients often avoid events for fear of seizures in public.
Improved seizure control means returning to these parts of life.

Family and Caregiver Burden in Arizona

Epilepsy doesn’t only affect the person having seizures—it impacts the entire family.

Parents of children with epilepsy: Miss work to attend appointments, face constant worry.
Spouses of adults with seizures: Take on driving duties, medication management, and emergency response roles.
Employers: Experience absenteeism and reduced productivity.

Phoenix families report that seizures are more than medical—they are emotional, social, and financial burdens.

By joining ANR’s epilepsy study, families gain:

Closer monitoring of their loved one’s condition.
Access to coordinators who provide support and education.
Hope that new therapies will reduce caregiver stress.

Economic Impact of Epilepsy in Phoenix

Lost Productivity: Epilepsy costs the U.S. billions annually. In Phoenix’s booming job sectors—healthcare, aerospace, and technology—the ripple effect is massive.
Healthcare Costs: Frequent ER visits at Banner or Abrazo cost patients and insurers thousands.
Driving Restrictions: Loss of a license forces families to spend on rideshare, taxis, or family time off work.
Insurance Barriers: Many ASMs are costly, with high co-pays or limited coverage.

ANR’s trial reduces this burden by offering:

No-cost study care and medication.
Reduction in ER visits through closer monitoring.
Improved patient function, boosting productivity and lowering costs for employers.

Phoenix Patient Story: Restoring Independence

Consider Luis, a 40-year-old father in Tempe. His partial-onset seizures prevent him from driving, forcing his wife to handle all transportation for their kids and household. Luis works remotely but struggles with fatigue and memory issues.

After enrolling in ANR’s epilepsy study:

Luis begins investigational therapy.
His seizure frequency decreases within months.
He regains confidence to return to in-office work.
His wife experiences relief, no longer bearing the full family burden.

For Luis and his family, ANR wasn’t just a trial site—it was a lifeline back to normalcy.

SEO Keyword Integration (Part 3)

This section naturally integrates:

epilepsy care Phoenix
neurologist Phoenix AZ
best neurologist in Phoenix Arizona
neurology clinic Phoenix
neurologist near me
neurology specialists Phoenix
brain scan center Phoenix
EEG testing Phoenix AZ
spine and brain health Phoenix

Supplementary clusters: Arizona neurology research studies, Phoenix neurologic disease experts, Arizona advanced neurology care.

Frequently Asked Questions (FAQ)

Q1. What is partial-onset epilepsy?
A neurological condition where seizures start in one region of the brain and may stay focal or spread to cause impaired awareness or generalized seizures.

Q2. How common is epilepsy in Phoenix?
Epilepsy affects about 1 in 26 people nationwide; Phoenix’s fast-growing and diverse population means tens of thousands live with epilepsy locally.

Q3. What are the symptoms of partial-onset seizures?
They may include strange sensations, déjà vu, confusion, repetitive movements, speech arrest, or convulsions if they spread.

Q4. How is epilepsy diagnosed?
Through medical history, seizure diaries, EEG testing, and brain imaging at facilities like [EEG Testing Phoenix AZ] and [Brain Scan Center Phoenix].

Q5. What treatments are available now?
Most patients are prescribed antiseizure medications (ASMs), though some need devices (VNS, RNS) or diets like keto.

Q6. Why do some people remain drug-resistant?
About one-third of patients don’t achieve seizure control despite trying two or more ASMs.

Q7. What makes this clinical trial important?
It tests a new investigational medication designed to reduce seizure frequency in patients with drug-resistant partial-onset epilepsy.

Q8. How long does the study last?
About 12–15 months, including screening, treatment, and extension phases.

Q9. How many visits are required?
Roughly 12–14 clinic visits at ANR Phoenix, plus some telehealth appointments.

Q10. Do I have to pay for the study?
No, study-related visits, tests, and medication are provided at no cost.

Q11. What if I already take seizure medications?
You may still qualify; ANR’s neurologists will review your regimen.

Q12. What are the age requirements?
18–75 years old.

Q13. Can children enroll?
Not in this particular study.

Q14. What if I live outside Phoenix?
Patients from Scottsdale, Mesa, Chandler, Tempe, Glendale, Paradise Valley, Arcadia, and Biltmore are welcome.

Q15. What happens if I get placebo?
After the blinded phase, you may transition to the investigational therapy in the extension.

Q16. Is the medication safe?
It has passed earlier phase studies and is monitored closely in this Phase 3 trial.

Q17. Who oversees the study?
The FDA, Institutional Review Boards (IRBs), and ANR neurologists.

Q18. What if I have a seizure during the study?
You’ll be supported by ANR staff with immediate care protocols.

Q19. Can I drop out?
Yes, participation is voluntary.

Q20. Will I be compensated?
Some trials reimburse for time and travel; coordinators will confirm details.

Q21. What if I’m pregnant?
Pregnancy is usually an exclusion for safety reasons.

Q22. Can I drive while in the study?
Arizona driving laws still apply—seizure-free intervals are required.

Q23. What if I miss a visit?
Coordinators will work with you to stay on track.

Q24. Will my insurance be billed?
No, study-related costs are covered.

Q25. Can I keep my neurologist?
Yes, you can continue regular care outside the study.

Q26. How are seizures tracked?
Through daily diaries on smartphone or provided devices.

Q27. Are there side effects?
Possible side effects vary; they’ll be explained in detail at screening.

Q28. How does this compare to Botox® or VNS?
It’s an oral therapy—non-invasive, unlike devices or injections.

Q29. Is the trial FDA-approved?
The investigational drug is not FDA-approved yet, but the trial is FDA-regulated.

Q30. How is epilepsy research advancing?
New medications, devices, and genetic insights are transforming treatment.

Q31. Why is Phoenix a key site?
Its diverse population and unique climate make data highly valuable.

Q32. Can Hispanic patients enroll?
Yes, ANR actively seeks diversity in enrollment.

Q33. Do I need a referral?
No referral required—patients can contact ANR directly.

Q34. What happens after the study?
Your care transitions back to your neurologist, with data contributing to global research.

Q35. Is my data safe?
Yes, privacy is protected under HIPAA and research regulations.

Q36. Can I join if I have other conditions?
Depends—eligibility is reviewed case by case.

Q37. Will I need labs or imaging?
Yes, periodic labs and brain scans may be part of monitoring.

Q38. Can I still work while in the study?
Yes, many visits can be scheduled around work hours.

Q39. What if I live in Glendale or Mesa?
ANR’s North Phoenix and Arcadia sites are accessible across the Valley.

Q40. Does weather affect epilepsy?
Yes, heat and monsoons can trigger seizures—local monitoring helps track this.

Q41. Are telehealth visits available?
Yes, some follow-ups are virtual.

Q42. How do I contact ANR?
Phone numbers and addresses are listed below.

Q43. What if I don’t qualify?
ANR runs other epilepsy and neurology trials you may be eligible for.

Q44. Can seniors enroll?
Yes, if under 75 and meeting criteria.

Q45. Will I get MRI or EEG scans?
Yes, depending on the protocol.

Q46. What if I’m uninsured?
Study costs are covered regardless of insurance.

Q47. Are there parking fees?
No, ANR offers free parking at both sites.

Q48. Can I enroll with Mayo or Banner care?
Yes, ANR collaborates but is independent, and enrollment is open.

Q49. Will results be shared?
Yes, at the conclusion of the study, global results are typically published.

Q50. Why choose ANR?
Because it is Phoenix’s #1 neurology research center—fast access, expert staff, and no-cost trial participation.

Supplemental Context

A Brief History of Epilepsy Research

Ancient cultures attributed seizures to spirits or curses.
In the 19th century, neurology began to identify abnormal brain activity as the cause.
The 20th century brought antiseizure drugs, but drug resistance remained a problem.
Now, 21st-century research—including Phoenix sites like ANR—focuses on targeted therapies, precision medicine, and improved quality of life.

Phoenix as a Hub for Neurology Research

Phoenix is not just a growing city; it’s becoming a healthcare powerhouse. With ANR at the center, Arizona contributes directly to global epilepsy research.

Diversity of participants strengthens scientific data.
Unique triggers (heat, monsoons, dust storms) provide insights other regions cannot.
Rapid population growth increases the demand for innovative neurology solutions.

ANR ensures Phoenix patients don’t have to wait for therapies developed elsewhere—they can participate here and now.

Final Calls to Action

For Phoenix residents struggling with partial-onset epilepsy:

Don’t wait months at Mayo or Banner.
Don’t accept repeated ER visits as the “new normal.”
Don’t let seizures define your independence.

Join the partial-onset epilepsy clinical trial at ANR today.

You may receive:

No-cost study medication and care.
Close monitoring from expert neurologists.
A chance to reduce seizure frequency and improve your life.

Contact ANR

📍 Arizona Neuroscience Research (ANR)

Arcadia/Biltmore Location:
4400 N 32nd St, Suite 150
Phoenix, AZ 85018
North Phoenix Location:
3805 E Bell Rd, Suite 2400
Phoenix, AZ 85032

📞 Main Line: (480) 210-8723
📞 Coordinator Direct: (602) 835-2407

➡️ Ask about the Partial-Onset Epilepsy Study (NCT04513860) today.